最新ニュース Eli Lilly (NYSE:LLY) 株価情報

Eli Lilly

Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.

Eli Lilly and Co

News

Upgrades

Pre-Market Outlook

Analyst Ratings

Trading Ideas

HOOD

TTWO

主要なアナリストが株式レーティングを見直したトピックスを紹介する。アナリストのレーティング変更（格上げ・格下げを含む）はアナリストレーティングのページをご覧いただきたい。

ロビンフッドのアナリスト　市場への評価を変更

Equities

Markets

ASTS

DXCM

TSLA

先週木曜日、主要な米国株指数は反発を推移した。ダウ平均は0.2%高の3万9935ドル、一方でS＆P500は0.5%安の5392ドルで取引を終了した。ナスダックは0.9%安の17182ドルで終了した。

米国株式市場　テスラが市場を牽引　NBA契約でディズニーも上昇

Short Sellers

Short Ideas

Eli Lilly and Co (NYSE:LLY) のフロートに対する新しいショート比率は、前回の報告から14.06％上昇しています。同社は最近、ショートで売られた株は616万株あり、これは取引可能なすべての普通株の0.73％に相当します。平均してこの株のショートポジションをカバーするには、トレーダーは2.39日かかります。

イーライリリー社をショート比率から分析

HARVEST ELI LILLY HG CL U UNT ETF

Liberty Media Corporation - Series A Liberty Live Common Stock

Liberty Live Group

LIBERTY LIVE SERIES B by Liberty Media Corporation

Liberty Media Corporation - Series C Liberty Live Common Stock

Tidal Trust II Defiance Daily Target 2X Long LLY ETF

Novartis (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/nvs#NYSE">NVS</a>) announced that the FDA has approved breast cancer drug Kisqali (ribociclib) for a broader population.
The regulatory body approved Kisqali in combination with an aromatase inhibitor for the adjuvant treatment of people with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) stage II and III early breast cancer (EBC) at high risk of recurrence, including those with node-negative (N0) disease.
Kisqali is a selective cyclin-dependent kinase inhibitor, a class of drugs that helps slow the progression of cancer by inhibiting two proteins &mdash; cyclin-dependent kinase 4 and 6 (CDK4/6).
The broad indication in HR+/HER2- stage II and III EBC at high risk of recurrence approximately doubles the population eligible for CDK4/6 inhibitor adjuvant therapy.
Year to date, shares of Novartis have risen 14.6% compared with the industry&#39;s growth of 24.1%.
<img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/e0/78240.jpg?v=1246149801" /> 
Image Source: Zacks Investment Research
<h2>Broader Label for NVS&#39; Kisqali</h2>
The FDA approval is based on strong results from the late-stage NATALEE trial. The results showed a significant and clinically meaningful 25.1% reduction in risk of disease recurrence in a broad population of patients with HR+/HER2- stage II and III EBC treated with adjuvant Kisqali plus endocrine therapy&nbsp;compared to ET alone, including those with high-risk N0 disease.
The invasive disease-free survival benefit was consistently observed across all patient subgroups.
Please note that Kisqali is already approved for the treatment of metastatic breast cancer (MBC) in several countries.
The latest FDA approval of Kisqali for this early breast cancer population, including those with N0 disease, should enable NVS to offer treatment with a CDK4/6 inhibitor to a significantly broader group of patients.
NVS recently presented an updated analysis from the NATALEE trial at the European Society for Medical Oncology Congress 2024. Results showed that Kisqali caused a deepening benefit beyond the three-year treatment period and reduced the risk of recurrence by 28.5% compared to ET alone, in patients with stage II and III HR+/HER2- EBC.
Novartis will continue to evaluate NATALEE patients for long-term outcomes, including overall survival.
<h2>Kisqali: A Top Drug for NVS</h2>
Kisqali is one of the key growth drivers for NVS, which is now a pure-play innovative medicine company with a focus on core therapeutic areas &mdash; cardiovascular, renal and metabolic, immunology, neuroscience and oncology.
It is one of the leading breast cancer drugs in the United States and outside the country, with a dominant market share. The drug generated sales worth $1.3 billion in the first half of 2024.
Approximately 90% of breast cancer cases in the United States are diagnosed early (stages I-III). These patients remain at risk of cancer recurrence (in most cases as an incurable metastatic disease).
The drug&#39;s approval for a broader population should further fuel sales.
Regulatory reviews for Kisqali as an EBC treatment are ongoing worldwide, including in the EU and China.
Last year, the FDA also expanded Eli Lilly&#39;s (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/lly#NYSE">LLY</a>) Verzenio&#39;s (abemaciclib) indication. Verzenio, a CDK4/6 inhibitor, was approved in combination with ET for the adjuvant treatment of HR+HER2-, node-positive, EBC at a high risk of recurrence.
Eli Lilly is witnessing a stupendous run in 2024, riding high on the success of its GLP-1 drugs &mdash; Mounjaro and Zepbound.
<h2>NVS&#39; Zacks Rank &amp; A Stock to Consider</h2>
NVS currently carries a Zacks Rank #3 (Hold).
A better-ranked stock from the large-cap pharma industry is Pfizer, which currently sports a Zacks Rank #2 (Buy).
Estimates for PFE&#39;s 2024 earnings have risen from $2.39 to $2.62 per share over the past 60 days. For 2025, the bottom-line estimate has risen from $2.75 to $2.85 over the same time frame.
<a href="https://www.zacks.com/stock/news/2337925/novartis-wins-fda-approval-of-kisqali-for-early-breast-cancer?cid=CS-BENZ-FT-analyst_blog|company_news_medical_sector-2337925">To read this article on Zacks.com click here.</a>

Earnings

Large Cap

Novartis Wins FDA Approval of Kisqali for Early Breast Cancer

Eli Lilly's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) short percent of float has risen 14.71% since its last report. The company recently reported that it has 6.27 million shares sold short, which is 0.78% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.41 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Eli Lilly Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1726605911_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Eli Lilly has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Eli Lilly's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Eli Lilly's peer group average for short interest as a percentage of float is 4.49%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Looking Into Eli Lilly's Recent Short Interest

Eli Lilly and Company (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/lly#NYSE">LLY</a>) announced that the FDA has granted approval to its IL-13 inhibitor Ebglyss (lebrikizumab) for treating moderate-to-severe atopic dermatitis, also called eczema. Ebglyss is approved for use in adults and children aged 12 and above who weigh at least 40 kgs and whose moderate-to-severe atopic dermatitis is not well controlled with topical prescription medicines.
Ebglyss was approved in the European Union in 2023 and in Japan in January this year. The drug generated sales of $7.5 million in the first half of 2024.
Year to date, Lilly&#39;s stock has risen 58.5% compared with the industry&#39;s 25.2% growth. The stock has also outperformed the sector as well as the S&amp;P 500.
<h2>LLY Stock Outperforms Industry, Sector &amp; S&amp;P 500</h2>
<img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/93/77794.jpg?v=624696101" style="height:310px; width:600px" />
Image Source: Zacks Investment Research
<h2>More on LLY&#39;s Ebglyss</h2>
Ebglyss&#39; approval in the United States was based on data from&nbsp;ADvocate 1, ADvocate 2 and ADhere studies. Data from these studies showed that patients treated with Ebglyss experienced significant skin clearance as early as four weeks and meaningful itch relief as early as two weeks. Many people living with eczema experience poor long-term disease control and severe itch despite treatment with topicals. Ebglyss offers such patients a new first-line biologic treatment option for treating their moderate-to-severe eczema. The injection will be launched in the United States in the coming weeks.
In the United States and some countries other than Europe, Lilly owns exclusive development and commercialization rights to Ebglyss. However, in Europe, it has out-licensed rights to develop and commercialize Ebglyss for the treatment of dermatology indications to its partner Almirall.
<h2>Lilly&#39;s Several New Drug Approvals in Past Year</h2>
Lilly gained approvals for some other new drugs in the past year, with the most important being Mounjaro and Zepbound. &nbsp;Mounjaro and Zepbound include the same compound, tirzepatide, a dual GIP and GLP-1 receptor agonist (GIP/GLP-1 RA). Mounjaro was approved in May 2022 for type II diabetes. Zepbound was launched in November 2023 to treat obesity.
Despite a short time on the market, Mounjaro and Zepbound have become key top-line drivers for Lilly in 2024, with demand rising rapidly. Mounjaro and Zepbound generated sales of almost $6.7 billion in the first half of 2024, accounting for around 44% of the company&#39;s total revenues.
Other than Mounjaro and Zepbound, other new drug approvals include Omvoh for ulcerative colitis and BTK inhibitor Jaypirca for mantle cell lymphoma and chronic lymphocytic leukemia. Lilly expects its new drugs &mdash; Mounjaro, Omvoh, Zepbound, Ebglyss and Jaypirca &mdash; to drive its top line in the second half of 2024.
In July, Lilly won a long-awaited FDA approval for Kisunla (donanemab) for treating early symptomatic Alzheimer&#39;s disease. Lilly believes Kisunla can generate blockbuster sales. Kisunla is only the second drug on the market to treat Alzheimer&#39;s disease after Biogen (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/biib#NASDAQ">BIIB</a>) and its Japan-based partner Eisai&#39;s Leqembi.
<h2>Lilly&#39;s Zacks Rank and Other Stocks to Consider</h2>
Lilly sports a Zacks Rank #1 (Strong Buy).
<div class="chart_embed">
<h3>Eli Lilly and Company Stock Price and Consensus</h3>
<img alt="Eli Lilly and Company Price and Consensus" src="https://staticx-tuner.zacks.com/images/charts/84/1726472114.png" style="height:265px; width:591px" title="" />
Eli Lilly and Company price-consensus-chart | Eli Lilly and Company Quote
Some other top-ranked large drugmakers are Novartis (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/nvs#NYSE">NVS</a>) and Pfizer (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/pfe#NYSE">PFE</a>), each carrying a Zacks Rank #2 (Buy).
</div>
In the past 60 days, 2024 earnings estimates for Pfizer have improved from $2.38 per share to $2.62 per share. For 2025, earnings estimates have improved from $2.75 per share to $2.85 per share over the same timeframe. Pfizer shares have risen 1.6% year to date.
Pfizer&#39;s earnings beat estimates in each of the last four quarters. PFE delivered a four-quarter average earnings surprise of 69.82%
Estimates for Novartis&#39; 2024 earnings have risen from $7.31 to $7.50 per share over the past 60 days. For 2025, earnings estimates have increased from $8.21 to $8.29 per share over the same timeframe. Year to date, Novartis stock has risen 14.5 %.
Novartis beat estimates in three of the last four quarters while missing in one, delivering a four-quarter average earnings surprise of 1.26%.
<a href="https://www.zacks.com/stock/news/2336877/lilly-gets-fda-approval-for-eczema-drug-ebglyss?cid=CS-BENZ-FT-analyst_blog|company_news_medical_sector-2336877">To read this article on Zacks.com click here.</a>

BIIB

Lilly Gets FDA Approval for Eczema Drug Ebglyss

Whales with a lot of money to spend have taken a noticeably bearish stance on Eli Lilly.
Looking at options history for Eli Lilly (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) we detected 30 trades.
If we consider the specifics of each trade, it is accurate to state that 30% of the investors opened trades with bullish expectations and 43% with bearish.
From the overall spotted trades, 4 are puts, for a total amount of $423,567 and 26, calls, for a total amount of $4,363,478.
<h3>Projected Price Targets</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $700.0 to $1100.0 for Eli Lilly during the past quarter. 
<h3>Insights into Volume &amp; Open Interest</h3>
In terms of liquidity and interest, the mean open interest for Eli Lilly options trades today is 498.6 with a total volume of 1,460.00.
In the following chart, we are able to follow the development of volume and open interest of call and put options for Eli Lilly's big money trades within a strike price range of $700.0 to $1100.0 over the last 30 days.
<h3>Eli Lilly Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1726582568_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th style="text-align: right;">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>LLY</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>11/15/24</td>
<td>$223.4</td>
<td>$217.55</td>
<td>$220.0</td>
<td>$700.00</td>
<td>$2.2M</td>
<td>836</td>
<td style="text-align: right;">300</td>
</tr>
<tr>
<td>LLY</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>01/17/25</td>
<td>$81.9</td>
<td>$80.95</td>
<td>$81.9</td>
<td>$900.00</td>
<td>$311.3K</td>
<td>1.8K</td>
<td style="text-align: right;">46</td>
</tr>
<tr>
<td>LLY</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>10/18/24</td>
<td>$28.3</td>
<td>$25.0</td>
<td>$25.0</td>
<td>$900.00</td>
<td>$300.4K</td>
<td>883</td>
<td style="text-align: right;">2</td>
</tr>
<tr>
<td>LLY</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>01/17/25</td>
<td>$119.15</td>
<td>$115.4</td>
<td>$119.15</td>
<td>$840.00</td>
<td>$273.9K</td>
<td>459</td>
<td style="text-align: right;">7</td>
</tr>
<tr>
<td>LLY</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>11/15/24</td>
<td>$51.65</td>
<td>$48.8</td>
<td>$48.8</td>
<td>$930.00</td>
<td>$239.1K</td>
<td>535</td>
<td style="text-align: right;">100</td>
</tr>
</tbody>
</table>

<h3>About Eli Lilly</h3>
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
Following our analysis of the options activities associated with Eli Lilly, we pivot to a closer look at the company's own performance.
<h3>Present Market Standing of Eli Lilly</h3>
<ul>
<li>Currently trading with a volume of 365,615, the LLY's price is down by -1.32%, now at $911.36. </li>
<li>RSI readings suggest the stock is currently may be approaching oversold.</li>
<li>Anticipated earnings release is in 44 days.</li>
</ul>
<h3>Professional Analyst Ratings for Eli Lilly</h3>
5 market experts have recently issued ratings for this stock, with a consensus target price of $1007.2.
<ul>
<li>In a cautious move, an analyst from Cantor Fitzgerald downgraded its rating to Overweight, setting a price target of $885. </li>
<li>Reflecting concerns, an analyst from Citigroup lowers its rating to Buy with a new price target of $1060.</li>
<li>Consistent in their evaluation, an analyst from JP Morgan keeps a Overweight rating on Eli Lilly with a target price of $1100. </li>
<li>In a cautious move, an analyst from Cantor Fitzgerald downgraded its rating to Overweight, setting a price target of $885. </li>
<li>An analyst from Morgan Stanley has revised its rating downward to Overweight, adjusting the price target to $1106. </li>
</ul>
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Eli Lilly with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

Options

Unpacking the Latest Options Trading Trends in Eli Lilly

Friday, the FDA approved Eli Lilly And Co&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) Ebglyss (lebrikizumab-lbkz), a targeted IL-13 inhibitor, for adults and children 12 years of age and older who weigh at least 88 pounds (40 kg) with moderate-to-severe atopic dermatitis (eczema) that is not well controlled despite treatment with <a target="_blank" href="https://www.benzinga.com/pressreleases/24/09/n40861537/fda-approves-lillys-ebglyss-lebrikizumab-lbkz-for-adults-and-children-12-years-and-older-with-mode" rel="noreferrer noopener">topical prescription therapies</a>.
Ebglyss works by targeting eczema inflammation throughout the body that can lead to dry, itchy, and irritated skin.
Ebglyss, 250 mg/2 mL injection, can be used with or without topical corticosteroids and is dosed as a monthly maintenance injection following the initial phase of treatment.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/24/09/40834619/eli-lilly-pumps-800m-into-irish-operations-to-meet-skyrocketing-demand-for-mounjaro-zepbound" rel="noreferrer noopener">Eli Lilly Pumps $800M Into Irish Operations To Meet Skyrocketing Demand For Mounjaro, Zepbound</a>.
The recommended initial starting dose of Ebglyss is 500 mg (two 250 mg injections) at Week 0 and Week 2, followed by 250 mg every two weeks until Week 16 or later when adequate clinical response is achieved; after this, maintenance dosing is a single monthly injection (250 mg every four weeks).
The approval was based on results from the ADvocate 1, ADvocate 2, and ADhere studies, which included over 1,000 adults and children (aged 12 and older) with moderate-to-severe eczema who could not control their symptoms with topical prescription medicines. The primary endpoint for these studies was evaluated at 16 weeks and measured clear or almost clear skin (IGA 0,1).
In an average of two studies (ADvocate 1 and 2), 38% of people who took Ebglyss achieved clear or almost clear skin at 16 weeks (versus 12% with placebo), and 10% saw these results as early as four weeks.
Of those who experienced clear or almost-clear skin at Week 16, 77% maintained those results at one year with once-monthly dosing. 48% of responders switched from Ebglyss to placebo at Week 16, maintained these results at one year.
Similarly, in both studies, many people experienced itch relief with Ebglyss.
On average, 43% of people who took Ebglyss felt itch relief at 16 weeks (compared to 12% who took a placebo), and 5% felt relief as early as two weeks.
Of the people who felt itch relief at Week 16, 85% still felt that relief at one year of treatment with monthly maintenance dosing. Sixty-six percent of responders switched from Ebglyss to placebo at Week 16 maintained these results at one year.
Price Action: LLY stock is up 0.28% at $925.90&nbsp;at last check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/24/09/40882969/iphone-16-pro-demand-lags-longer-wait-times-globally-china-shows-smaller-gap-analyst" target="_blank" rel="noreferrer noopener">iPhone 16 Pro Demand Lags, Longer Wait Times Globally, China Shows Smaller Gap: Analyst</a>.</li>
</ul>
Photo via Shutterstock

Biotech

Health Care

General

Eli Lilly Scores FDA Approval For Eczema Treatment Ebglyss

Cantor Fitzgerald analyst Louise Chen reiterates Eli Lilly (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) with a Overweight and maintains $885 price target.

Price Target

Reiteration

Cantor Fitzgerald Reiterates Overweight on Eli Lilly, Maintains $885 Price Target

FDA Approves Lilly's Ebglyss For Adults And Children 12 Years And Older With Moderate-To-Severe Atopic Dermatitis

Correction: JP Morgan analyst Chris Schott maintains Eli Lilly (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) with a Overweight and raises the price target from $1050 to $1100. Action Price target changed to Raises

Correction: JP Morgan Maintains Overweight on Eli Lilly, Raises Price Target to $1100. Action Price target changed to Raises

JP Morgan analyst Chris Schott maintains Eli Lilly (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) with a Overweight and lowers the price target from $1050 to $1100.

JP Morgan Maintains Overweight on Eli Lilly, Lowers Price Target to $1100

Citigroup analyst Peter Verdult reinstates Eli Lilly (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) with a Buy and announces $1060 price target.

Initiation

Citigroup Reinstates Buy on Eli Lilly, Announces $1060 Price Target

Deep-pocketed investors have adopted a bullish approach towards Eli Lilly (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in LLY usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 90 extraordinary options activities for Eli Lilly. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 55% leaning bullish and 33% bearish. Among these notable options, 20 are puts, totaling $654,388, and 70 are calls, amounting to $15,760,820.
<h3>Expected Price Movements</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $240.0 to $1300.0 for Eli Lilly over the recent three months. 
<h3>Volume &amp; Open Interest Trends</h3>
In terms of liquidity and interest, the mean open interest for Eli Lilly options trades today is 469.93 with a total volume of 18,909.00.
In the following chart, we are able to follow the development of volume and open interest of call and put options for Eli Lilly's big money trades within a strike price range of $240.0 to $1300.0 over the last 30 days.
<h3>Eli Lilly Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1726169563_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>LLY</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>11/15/24</td>
<td>$123.05</td>
<td>$120.3</td>
<td>$123.0</td>
<td>$840.00</td>
<td>$1.2M</td>
<td>2.2K</td>
<td>1.2K</td>
</tr>
<tr>
<td>LLY</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>11/15/24</td>
<td>$121.3</td>
<td>$119.9</td>
<td>$121.0</td>
<td>$840.00</td>
<td>$1.2M</td>
<td>2.2K</td>
<td>1.6K</td>
</tr>
<tr>
<td>LLY</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>11/15/24</td>
<td>$119.65</td>
<td>$117.5</td>
<td>$119.5</td>
<td>$840.00</td>
<td>$1.1M</td>
<td>2.2K</td>
<td>1.0K</td>
</tr>
<tr>
<td>LLY</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>11/15/24</td>
<td>$119.25</td>
<td>$117.0</td>
<td>$119.1</td>
<td>$840.00</td>
<td>$1.1M</td>
<td>2.2K</td>
<td>1.1K</td>
</tr>
<tr>
<td>LLY</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>11/15/24</td>
<td>$117.0</td>
<td>$115.45</td>
<td>$116.8</td>
<td>$840.00</td>
<td>$1.1M</td>
<td>2.2K</td>
<td>922</td>
</tr>
</tbody>
</table>

<h3>About Eli Lilly</h3>
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
Following our analysis of the options activities associated with Eli Lilly, we pivot to a closer look at the company's own performance.
<h3>Eli Lilly's Current Market Status</h3>
<ul>
<li>Currently trading with a volume of 1,616,149, the LLY's price is up by 0.23%, now at $923.0. </li>
<li>RSI readings suggest the stock is currently may be approaching overbought.</li>
<li>Anticipated earnings release is in 49 days.</li>
</ul>
<h3>Professional Analyst Ratings for Eli Lilly</h3>
Over the past month, 5 industry analysts have shared their insights on this stock, proposing an average target price of $991.2.
<ul>
<li>Reflecting concerns, an analyst from Morgan Stanley lowers its rating to Overweight with a new price target of $1106.</li>
<li>Reflecting concerns, an analyst from Cantor Fitzgerald lowers its rating to Overweight with a new price target of $885.</li>
<li>Consistent in their evaluation, an analyst from Berenberg keeps a Buy rating on Eli Lilly with a target price of $1050. </li>
<li>Consistent in their evaluation, an analyst from Guggenheim keeps a Buy rating on Eli Lilly with a target price of $1030. </li>
<li>An analyst from Cantor Fitzgerald downgraded its action to Overweight with a price target of $885. </li>
</ul>
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Eli Lilly options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

Looking At Eli Lilly's Recent Unusual Options Activity

In a bid to meet escalating demand for its obesity drugs, pharmaceutical behemoth, Eli Lilly &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) has funneled $800 million into its Irish operations to ramp up the production of its blockbuster drugs, Mounjaro and Zepbound.
What Happened: The investment is aimed at ensuring a steady supply of the drugs, which have been grappling with shortages since 2022. The facility, situated near the town of Kinsale in County Cork, Ireland, will manufacture tirzepatide, the key ingredient in these injectable medicines, Bloomberg <a href="https://www.bloomberg.com/news/articles/2024-09-12/lilly-bulks-up-irish-operations-in-obesity-drug-production-push?srnd=homepage-americas">reported</a> on Thursday.
The decision comes in the wake of the U.S. government&#8217;s stringent measures against Chinese biotech firms, a significant contributor to the global pharmaceutical supply chain. 
The company has embraced a hybrid manufacturing strategy that enhances output while mitigating the complexities of delicate peptide production. The plant was recently dubbed a "Facility of the Year" by the International Society for Pharmaceutical Engineering for its innovative approach.
See Also: <a href="https://www.benzinga.com/partner/health-care/24/09/40748041/no-more-wisdom-teeth-horror-stories-triagenics-alternative-to-painful-wisdom-teeth-removal?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">No More Wisdom Teeth Horror Stories? TriAgenics&#8217; Alternative To Painful Wisdom Teeth Removal</a>
Since 2020, Lilly has been steadily increasing its production capacity, pouring over $17 billion into the creation of new plants and expansion of existing facilities for its weight-loss and diabetes drugs. The company has also initiated the construction of production capacity for its next-generation weight-loss medicines, which are currently in clinical trials.
Why It Matters: Eli Lilly&#8217;s investment in its Irish operations comes amidst a mixed outlook from 28 analysts, with an average <a href="https://www.benzinga.com/insights/analyst-ratings/24/09/40781213/a-glimpse-into-the-expert-outlook-on-eli-lilly-through-28-analysts">12-month price target</a> of $964.46 for the company&#8217;s stock. The company has been battling imitation versions of Mounjaro and Zepbound, launching discounted products to<a href="https://www.benzinga.com/markets/equities/24/09/40672154/eli-lilly-launches-discounted-mounjaro-and-zepbound-as-fight-against-compounded-imitations-escal"> counter off-brand versions</a>.
The company&#8217;s second-quarter results, driven by the popularity of Mounjaro and Zepbound, surpassed estimates, with revenue rising<a href="https://www.benzinga.com/news/24/08/40369350/eli-lilly-smashed-estimates-thanks-to-unbelievable-demand-for-its-diabetes-and-weight-loss-blockbust"> nearly 36% to $11.30 billion</a>. The company&#8217;s commitment to boosting production capacity underscores its leading position in the lucrative weight loss field.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/24/09/40786879/apples-airpods-pro-2-bring-clinical-grade-hearing-aid-without-the-stigma-or-high-cost-heres-what-peo?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Apple&#8217;s AirPods Pro 2 Bring &#8216;Clinical-Grade Hearing Aid&#8217; Without The Stigma Or High Cost: Here&#8217;s What People Have To Say</a></li>
</ul>
Disclaimer: This content was partially produced with the help of <a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noreferrer noopener">Benzinga Neuro</a> and was reviewed and published by Benzinga editors.
Image via Shutterstock

Eli Lilly Pumps $800M Into Irish Operations To Meet Skyrocketing Demand For Mounjaro, Zepbound

Financial giants have made a conspicuous bearish move on Eli Lilly. Our analysis of options history for Eli Lilly (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) revealed 22 unusual trades.
Delving into the details, we found 31% of traders were bullish, while 40% showed bearish tendencies. Out of all the trades we spotted, 3 were puts, with a value of $79,790, and 19 were calls, valued at $3,152,686.
<h3>What's The Price Target?</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $240.0 to $1180.0 for Eli Lilly over the last 3 months. 
<h3>Volume &amp; Open Interest Development</h3>
Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Eli Lilly's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Eli Lilly's significant trades, within a strike price range of $240.0 to $1180.0, over the past month.
<h3>Eli Lilly Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1726149751_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th style="text-align: right;">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>LLY</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>12/19/25</td>
<td>$700.0</td>
<td>$690.0</td>
<td>$694.0</td>
<td>$240.00</td>
<td>$1.3M</td>
<td>17</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>LLY</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>11/15/24</td>
<td>$112.0</td>
<td>$108.65</td>
<td>$112.0</td>
<td>$840.00</td>
<td>$560.0K</td>
<td>2.2K</td>
<td style="text-align: right;">50</td>
</tr>
<tr>
<td>LLY</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>09/13/24</td>
<td>$7.0</td>
<td>$6.0</td>
<td>$6.51</td>
<td>$925.00</td>
<td>$333.3K</td>
<td>359</td>
<td style="text-align: right;">708</td>
</tr>
<tr>
<td>LLY</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>09/13/24</td>
<td>$8.4</td>
<td>$6.8</td>
<td>$6.8</td>
<td>$925.00</td>
<td>$102.0K</td>
<td>359</td>
<td style="text-align: right;">858</td>
</tr>
<tr>
<td>LLY</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>09/13/24</td>
<td>$3.2</td>
<td>$2.7</td>
<td>$3.19</td>
<td>$935.00</td>
<td>$79.6K</td>
<td>530</td>
<td style="text-align: right;">70</td>
</tr>
</tbody>
</table>

<h3>About Eli Lilly</h3>
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
<h3>Where Is Eli Lilly Standing Right Now?</h3>
<ul>
<li>Currently trading with a volume of 233,725, the LLY's price is up by 0.08%, now at $921.59. </li>
<li>RSI readings suggest the stock is currently is currently neutral between overbought and oversold.</li>
<li>Anticipated earnings release is in 49 days.</li>
</ul>
<h3>Professional Analyst Ratings for Eli Lilly</h3>
A total of 5 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $991.2.
<ul>
<li>An analyst from Berenberg persists with their Buy rating on Eli Lilly, maintaining a target price of $1050. </li>
<li>Consistent in their evaluation, an analyst from Guggenheim keeps a Buy rating on Eli Lilly with a target price of $1030. </li>
<li>In a cautious move, an analyst from Morgan Stanley downgraded its rating to Overweight, setting a price target of $1106. </li>
<li>In a cautious move, an analyst from Cantor Fitzgerald downgraded its rating to Overweight, setting a price target of $885. </li>
<li>An analyst from Cantor Fitzgerald downgraded its action to Overweight with a price target of $885. </li>
</ul>
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Eli Lilly, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

This additional investment is part of the most ambitious manufacturing expansion agenda in the company&#39;s history. Since 2020, Lilly has committed more than&nbsp;$20 billion&nbsp;to build, expand and acquire manufacturing facilities in the U.S. and&nbsp;Europe.

Eli Lilly Boosts Manufacturing Investment In Limerick, Ireland, By $1B; Unveils New $800M Kinsale Facility

RHHBY

Roche Says In CT-996 Phase 1 Trial, 4-Week Weight Loss Was 5.8% In Second-Best-Performing Cohort Vs 1.2% Weight Loss In Placebo Cohort; Placebo-Adjusted Average Weight Loss Of 6.1% From CT-996 Obesity Pill Trial Was From 1 Of 3 Active Cohorts In The Phase I Trial; In CT-996 Phase 1 Trial, 4-Week Weight Loss Was 7.3% In Best-Performing Cohort With 6 Patients Vs 1.2% Weight Loss In Placebo Cohort

Billionaire Elon Musk is the world's richest person and also an influential figure<a href="https://www.benzinga.com/general/education/24/06/39547388/happy-birthday-elon-musk-53-facts-and-figures-about-tesla-spacex-ceo-on-his-53rd-birthday"> across several business segments </a>thanks to his leadership at companies like Tesla Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>), X, xAI, SpaceX, Neuralink and The Boring Company.
Musk could become a trillionaire in the future, thanks in large part to one of the above companies.
What Happened: Musk&#8217;s wealth is a dream for most and a challenge <a href="https://www.benzinga.com/general/education/24/09/40686893/elon-musk-is-so-rich-that-if-you-printed-1m-a-day-since-the-renaissance-you-still-wouldnt-catch">for others to match.</a>
Currently listed with a wealth of $241 billion, Musk has a near $50-billion lead on second place Jeff Bezos ($198 billion) according to valuation rankings from <a href="https://www.bloomberg.com/billionaires/">Bloomberg</a>.
A new <a href="https://informaconnect.com/academy/companies-entering-trillion-dollar-club-in-2024/">study </a>from Informa Connect Academy found that Musk's wealth grows at an average annual growth rate of 109.9%. While several other billionaires have higher growth rates like Gautam Adani (+122.9%) and Jensen Huang (+111.9%), Musk is predicted to become the world's first trillionaire.
The study projects Musk will reach the wealth milestone by 2027, assuming Tesla maintains its impressive annual growth rate of 173.3%.
Musk's wealth is highly concentrated from stakes of around 13% and 42% in Tesla and SpaceX respectively, with Tesla being the more liquid wealth provider with shares publicly traded, often changing Musk's wealth levels on the daily.
Tesla, which was previously valued at $1 trillion, is expected to return to the limited club of companies worth $1 trillion or more in 2025.
Did You Know?
<ul>
<li>Congress Is Making Huge Investments. <a href="https://www.benzinga.com/gov-trades/?utm_source=BZprocontent091024">Get Tips On What They Bought And Sold Ahead Of The 2024 Election With Our Easy-to-Use Tool</a></li>
</ul>
What's Next: Informa Connect Academy predicts that Musk will be followed by others in the trillionaire race, with Adani and Huang expected to join in 2028.
Two of the largest gainers in 2024 for wealth have been Huang, gaining $49.6 billion and Meta Platforms CEO Mark Zuckerberg gaining $51.4 billion. Musk, on the other hand, has only gained $11.7 billion in 2024. This ranks sixth among the top 10 richest people.
Musk's wealth has faced wide swings previously. In 2022, Musk saw his wealth fall by more than $180 billion setting a<a href="https://www.benzinga.com/news/23/01/30362822/elon-musk-wins-a-guinness-world-record-but-he-likely-wont-be-celebrating"> new Guinness World Record</a>, with Tesla stock falling over 60% for the year. The high volatility of Musk-linked companies could cause his path to trillionaire status to be faster or slower than the report predicts.
Musk's rival Bezos isn't predicted to become a trillionaire until 2036, with his average annual wealth growing at only 15.3%. While Zuckerberg has the top wealth gain this year, his 35.8% average annual rate is also lower than many top billionaires. Zuckerberg is predicted to become a trillionaire in 2030.
Conglomerate Berkshire Hathaway recently<a href="https://www.benzinga.com/top-stories/24/08/40604676/warren-buffetts-berkshire-hathaway-breaks-1-trillion-poll-points-to-big-pharma-not-tech-as-next-cont"> joined the $1 trillion </a>market capitalization club and the study predicts that Tesla, Taiwan Semiconductor Manufacturing (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSM#NYSE">TSM</a>), Eli Lilly (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) and Broadcom (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGO#NASDAQ">AVGO</a>) could all join the club in 2025. Eli Lilly came on top in a Benzinga reader poll of which company would top $1 trillion next, after Berkshire Hathaway.
Other future $1 trillion companies are expected to be Novo Nordisk in 2026 and the likes of Exxon Mobil, ASML, and Advance Micro Devices in 2028.
Check This Out:
<ul>
<li>Lawmakers Made Huge Investments This Year. <a href="https://www.benzinga.com/gov-trades/?utm_source=BZprocontent091024">Get Tips On What They Bought And Sold Ahead Of The 2024 Election With Our Easy-to-Use Tool</a></li>
</ul>
Photo: Shutterstock

Topics

Management

AVGO

Could Elon Musk Become The World's First Trillionaire? Tesla's Success Could Make It Happen As Early As...

At the European Association for the Study of Diabetes annual meeting, Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) shared an abstract with data from the company&#8217;s next-generation <a target="_blank" href="https://www.benzinga.com/general/biotech/24/03/37562828/novo-nordisk-sets-timeframe-for-its-next-gen-experimental-obesity-drug" rel="noreferrer noopener">weight loss candidate, amycretin</a>.
Earlier today, Novo Nordisk&nbsp;announced that its weight-loss drug liraglutide is safe and effective for children <a target="_blank" href="https://www.benzinga.com/markets/equities/24/09/40809053/novo-nordisk-reports-positive-results-of-weight-loss-drug-liraglutide-for-children-as-young-as-6" rel="noreferrer noopener">as young as six</a>.
The company-funded study revealed a 7.4% reduction in body mass index for children aged 6 to 12 who used the injectable pens over a year compared to a placebo group.
Amycretin is a novel protein-based unimolecular amylin (regulates hunger) and GLP-1 receptor co-agonist for once-daily oral administration.
GLP-1 (produced in the small intestine to regulate blood sugar) is the same hormone targeted by other weight loss drugs like Novo Nordisk&#8217;s Wegovy (semaglutide) and Eli Lilly And Co&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) Zepbound (tirzepatide).
In a single-center, placebo-controlled, double-blinded <a target="_blank" href="https://www.easd.org/media-centre/home.html#!resources/b-safety-tolerability-and-weight-reduction-findings-of-oral-amycretin-a-novel-amylin-and-glucagon-like-peptide-1-receptor-co-agonist-in-a-first-in-human-study-b-70062cca-bdca-47a3-a603-124d45236f6f" rel="noreferrer noopener">study</a>, adult participants with a BMI of 25.0-39.9 kg/m2 without diabetes were randomized to receive amycretin or a placebo once a day for up to 12 weeks.
In the first-in-human trial, a 50-mg dose of the daily pill of amycretin, led to 10.4% weight loss at about three months after the start of treatment.
Participants who took two 50-mg pills daily lost 13.1% of their weight compared to 1.1% in the placebo group for both doses.
According to Novo Nordisk, the drug is safe, with side effects in line with those of Ozempic and Wegovy.
Most adverse events reported were mild to moderate in severity and related to gastrointestinal discomfort (e.g., nausea, vomiting), and decreased appetite.
In a similar&nbsp;trial, participants who were taking Wegovy showed a weight loss of&nbsp;<a target="_blank" href="https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2796491" rel="noreferrer noopener">5.9%</a> after 12 weeks.
Wegovy&nbsp;<a target="_blank" href="https://www.wegovy.com/about-wegovy/why-wegovy.html" rel="noreferrer noopener">showed</a> an overall weight loss of 15% after two years of treatment vs. 2.6% (~6 lb) for adults taking a placebo.
At the end of the treatment period, participants taking amycretin did not reach a plateau in weight loss, indicating the potential for further weight loss with extended use.
The study&#8217;s authors conclude that daily oral amycretin treatment in adults who are overweight or obese and without diabetes demonstrated a safe and tolerable profile in line with the drug receptor classes and with notable reductions in body weight.
&#8220;A single molecule that targets both amylin and GLP-1 biology in a tablet form could offer a more convenient approach to achieving better outcomes for individuals with overweight or obesity,&#8221; researchers <a target="_blank" href="https://www.yahoo.com/news/ozempic-maker-touts-remarkable-more-220100220.html" rel="noreferrer noopener">said</a> before presenting the findings.
Price Action: NVO stock is up 2.53% at $133.06 during the premarket session at last check Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/09/40802152/neurology-focused-harmony-biosciences-gains-confidence-with-wakix-sales-surge-strat" target="_blank" rel="noreferrer noopener">Neurology-Focused Harmony Biosciences Gains Confidence With Wakix Sales Surge, Strategic Pipeline Expansion, Bullish Analyst Says</a>.</li>
</ul>
Ozempic injection Image By Natalia Varlei On Shutterstock

Movers

Ozempic Maker Novo Nordisk Touts Encouraging Data From New Obesity Pill Showing Double Weight Loss Compared To Wegovy

Novo Nordisk (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) has announced that its weight-loss drug liraglutide is safe and effective for children as young as six. The company-funded study revealed a 7.4% reduction in body-mass index for children aged 6 to 12 using the injectable pens over a year compared to a placebo group.
What Happened: The study, involving 82 children, indicates liraglutide could become the first obesity treatment available for this age group. Martin Holst Lange, Novo Nordisk's head of development, stated the company will seek regulatory approval from the U.S. Food and Drug Administration and the European Medicines Agency, <a href="https://www.ft.com/content/83bfafb7-72a4-455f-8def-0caa959def3d">reported</a> the Financial Times.
"One in five children have obesity and one of the biggest predictors for adult obesity is childhood obesity so having this potential intervention for that age group is important," Lange said, according to the report. 
Currently, no pharmaceutical treatments for general obesity in under-12s exist, according to Claudia Fox from the University of Minnesota Medical School, who led the study. Novo Nordisk is also testing semaglutide, the active ingredient in Ozempic and Wegovy, for young children, which is already approved for over-12s.
Despite promising results, side effects such as nausea and vomiting were noted, and weight was quickly regained after stopping the drug. However, there were no differences in growth, bone age, or puberty issues between the control group and those on liraglutide, Fox added.
See Also: <a href="https://www.benzinga.com/news/24/09/40743718/mark-cuban-says-kamala-harris-is-simply-doing-what-trump-did-in-2016-its-her-party-she-gets-to-set-t?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Mark Cuban Says Kamala Harris Is Simply Doing What Trump Did In 2016: &#8216;It&#8217;s Her Party. She Gets To Set The Rules&#8217;</a>
Why It Matters: The announcement from Novo Nordisk comes at a time when the <a href="https://www.benzinga.com/general/biotech/24/09/40737027/fake-ozempic-targets-weight-loss-market-forged-batches-an-international-concern">weight-loss drug market</a> is under intense scrutiny. Recently, there have been concerns about the distribution of fake versions of weight-loss drugs like Ozempic. Criminals have been forging drug batch numbers to produce counterfeit versions, raising international concerns.
Moreover, research has revealed that semaglutide, the <a href="https://www.benzinga.com/markets/equities/24/08/40667073/ozempic-unexpected-anti-aging-miracle-drug-researchers-reveal-surprising-potential">active ingredient in Ozempic</a>, might have unexpected benefits beyond weight loss. According to researchers, the drug could potentially address a range of ailments, including heart failure, arthritis, Alzheimer's, and even cancer.
In addition, the market for weight-loss drugs is rapidly expanding, with companies like Hims &amp; Hers Health Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>) offering affordable alternatives to popular medications due to <a href="https://www.benzinga.com/markets/equities/24/08/40667073/ozempic-unexpected-anti-aging-miracle-drug-researchers-reveal-surprising-potential">high demand and occasional shortages</a>. However, the sustainability of these alternatives is under question as pharmaceutical giants ramp up production to meet demand.
Furthermore, Eli Lilly (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) has launched discounted versions of its <a href="https://www.benzinga.com/markets/equities/24/09/40672154/eli-lilly-launches-discounted-mounjaro-and-zepbound-as-fight-against-compounded-imitations-escal">appetite-suppressing drugs</a>, Mounjaro and Zepbound, to combat imitation versions and address regulatory debates over drug shortages. 
Price Action: Novo Nordisk closed at $129.78 on Tuesday, down 1.61% for the day. In after-hours trading, the stock saw a slight uptick, rising 0.54%. Year to date, the stock has gained 27.10%, according to <a href="https://pro.benzinga.com/dashboard">data from Benzinga Pro</a>.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/24/09/40772224/this-analyst-with-83-accuracy-rate-sees-more-than-36-upside-in-alphabet-here-are-5-stock-picks-for-a?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">This Analyst With 83% Accuracy Rate Sees More Than 36% Upside In Alphabet &#8211; Here Are 5 Stock Picks For August From Wall Street&#8217;s Most Accurate Analysts</a></li>
</ul>
Image Via Shutterstock 
This story was generated using <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a> and edited by <a href="https://www.benzinga.com/topic/Kaustubh-Bagalkote" target="_blank" rel="noreferrer noopener">Kaustubh Bagalkote</a>

Hims & Hers Health, Inc. Class A Common Stock

HIMS

Novo Nordisk Reports Positive Results Of Weight-Loss Drug Liraglutide For Children As Young As 6, Eyes FDA And EMA Approval

Eli Lilly (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) has outperformed the market over the past 20 years by 5.71% on an annualized basis producing an average annual return of 13.92%. Currently, Eli Lilly has a market capitalization of $810.81 billion. 
Buying $100 In LLY: If an investor had bought $100 of LLY stock 20 years ago, it would be worth $1,348.82 today based on a price of $900.47 for LLY at the time of writing.
<h3>Eli Lilly's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1725998417_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much You Would Have Made Owning Eli Lilly Stock In The Last 20 Years

Shares of Terns Pharmaceuticals (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tern#NASDAQ">TERN</a>), a clinical-stage company, soared 16.8% after the company announced positive top-line data from the early-stage single and multiple-ascending dose (SAD and MAD) obesity study. The phase I study evaluated the safety, tolerability, pharmacokinetics and pharmacodynamics of its investigational, oral, small-molecule&nbsp;GLP-1R agonist, TERN-601, dosed once daily in healthy adults with obesity or overweight.
<h2>Terns Reports Superior Weight Reduction With TERN-601</h2>
Per the data readout from the phase I obesity study, treatment with TERN-601 led to dose-dependent, statistically significant placebo-adjusted mean weight loss across all three doses (240 mg, 500 mg and 740 mg) evaluated in the 28-day MAD study.
The maximum placebo-adjusted mean weight loss of 4.9% was observed at the highest dose of TERN-601 (740 mg), administered once daily. It was also observed that 67% of the patients treated with the candidate, lost 5% or more of their baseline body weight at the 740 mg dosage strength of TERN-601.
Additionally, Terns Pharmaceuticals reported that the candidate was generally safe and overall well-tolerated in the phase I obesity study. Despite fast titration to high doses, no treatment-related dose interruptions, reductions or discontinuations at any dose strength were observed. Treatment-related adverse events were mostly mild to moderate in severity. Importantly, no clinically meaningful changes in liver enzymes, vital signs or electrocardiograms were observed.
Year to date, shares of TERN have jumped 40.5% against the industry&#39;s 1.6% decline.
<img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/a9/77177.jpg?v=1148197964" style="height:310px; width:600px" />
Image Source: Zacks Investment Research
Based on such encouraging results, TERN believes that TERN-601 has the potential to be a class-leading GLP-1R agonist for weight management. The candidate&#39;s distinct properties, like low solubility and high gut permeability, could result in a prolonged duration of efficacy thatmay be advantageous as an oral GLP-1R agonist.
<h2>Terns&#39; Future Plans for TERN-601 in Weight Management</h2>
Per management, the positive results from the phase I study underscore the potential of TERN-601 to be developed for treating obesity as a monotherapy or in combination with other agents. Terns Pharmaceuticals expects to initiate a phase II study of TERN-601 for the obesity indication in 2025.
The company stated that it has already successfully identified an optimal range of clinically active, well-tolerated doses for phase II development and does not anticipate any new dose range exploration.
<div class="chart_embed">
<h2>Terns Pharmaceuticals, Inc. Price and Consensus</h2>
<img alt="Terns Pharmaceuticals, Inc. Price and Consensus" src="https://staticx-tuner.zacks.com/images/charts/ba/1725977062.png" style="height:310px; width:600px" title="" />
Terns Pharmaceuticals, Inc. price-consensus-chart | Terns Pharmaceuticals, Inc. Quote
</div>
<h2>Other Players Operating in the Obesity Market</h2>
The obesity market is currently dominated by two large drugmakers, Eli Lilly (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/lly#NYSE">LLY</a>) and Novo Nordisk (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/nvo#NYSE">NVO</a>),&nbsp;with their respective obesity drugs Zepbound and Wegovy. Despite having approved drugs in this space, LLY and NVO have been unable to cope with existing demand.
Eli Lilly launched its obesity drug, Zepbound,a dual GIP and GLP-1R agonist in November 2023. Zepbound has seen a strong uptake since its launch. The drug generated revenues of $1.76 billion in the first half of 2024.
On the other hand, Wegovy, a GLP-1 agonist, is NVO&#39;s blockbuster chronic weight management injection approved for adults with obesity or overweight. The drug received FDA approval in 2021 and has witnessed stellar performance ever since. In the first half of 2024, Wegovy sales generated DKK 21 billion in revenues.
Amgen&nbsp;(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/amgn#NASDAQ">AMGN</a>) is also developing MariTide (maridebart cafraglutide), a GIPR/GLP-1 receptor for obesity in its pipeline. In May, Amgen stated that it was &quot;very encouraged&quot; by the interim data from the phase II study on MariTide. Top-line 52-week data from the phase II study on MariTide in adults with overweight or obesity is expected in late 2024. AMGN is planning to conduct a comprehensive phase III program on the candidate across obesity, obesity-related conditions and type-II diabetes.
Per research conducted by Goldman Sachs, the obesity market in the United States is expected to reach $130 billion by 2030. This is also evident from the fact that Lilly and Novo Nordisk are investing heavily to optimize their production capacities and have started evaluating multiple other novel obesity candidates.
<h2>Zacks Rank</h2>
Terns Pharmaceuticals currently carries a Zacks Rank #2 (Buy).
<a href="https://www.zacks.com/stock/news/2334185/terns-stock-soars-on-positive-data-from-phase-i-study-of-obesity-drug?cid=CS-BENZ-FT-analyst_blog|company_news_medical_sector-2334185">To read this article on Zacks.com click here.</a>

Small Cap

AMGN

TERN

Terns Stock Soars on Positive Data From Phase I Study of Obesity Drug

BlackRock Capital Appreciation VI Fund Q2 2024 Commentary

Multiple Strong Catalysts And Attractive Valuation Make Novo Nordisk A Buy

Sen. Sanders says generic drugmakers willing to sell Ozempic for less than $100

ResMed slips as Wolfe downgrades on GLP-1 threat from Lilly

Indices/Mag 10 Stocks Still Below All-Time Highs

Vanda slips as FDA rejects therapy for stomach condition

Weight loss drug developer BioAge seeks up to $602M valuation in U.S. IPO

American Century Growth Fund Q2 2024 Commentary

Novo Nordisk: The Street Is Not Seeing The Growth Acceleration Potential

Tandem Diabetes rises as insulin pump cleared for use in EU with Lilly insulin

AAPL

ABBV

AFMC

AMZN

ARKK

ASML

BBMC

BFOR

BIOA

BKMC

BMVP

BOUT

CRWD

DDIV

DEUS

DVLU

EQAL

ETHO

FFSM

FFTY

FLQM

FOVL

FRTY

FSCS

FSMD

FTDS

GOOG

GOOGL

GRPM

HAIL

HLGE

HOMZ

IMCB

IMCG

IMCV

INTU

IVOG

IVOO

IVOV

JHMM

JPME

JSMD

KOMP

LSAT

MDYG

MDYV

MIDE

MSFT

NAPR

NJAN

NONOF

NUMG

NUMV

NVDA

ONEO

ONEQ

ONEV

ONEY

PAMC

PEXL

PINS

PTMC

QMOM

QQEW

QQQA

QQQE

QQQJ

QQQM

QQQN

QQXT

QTEC

QVAL

QVMM

QYLD

QYLG

REGL

RSPT

SAIA

SBUX

SCHM

SDVY

SFYX

SIXL

SMDY

SPMD

SQEW

SYLD

TMDV

TNDM

TPHD

TPLC

UPGD

USMF

VFMF

VFMO

VFMV

VFQY

VFVA

VNDA

VRAI

VUSE

WBIY

XMHQ

Comments

Eli Lilly

ニュース

最新ニュース Eli Lilly (NYSE:LLY) 株価情報

月曜日, 8 12, 2024

金曜日, 7 26, 2024

水曜日, 6 19, 2024

火曜日, 5 07, 2024

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル